Potentially overcoming Crizotinib resistance in ROS1

Cabozantinib appears to overcome crizotinib resistance in ROS1 fusion positive cancer.

http://www.ncbi.nlm.nih.gov/pubmed/25351743

This entry was posted in Uncategorized. Bookmark the permalink.

Leave a Reply